March 16, 2019 / 12:07 AM / 5 months ago

Vanda loses bid to proceed with drug trial while FDA reconsiders hold

A federal judge ruled on Thursday that Vanda Pharmaceuticals Inc could not proceed with a human clinical trial for its gastrointestinal drug tradipitant while the U.S. Food and Drug Administration weighs requiring months of additional animal toxicity testing.

Vanda sued the FDA on Feb. 5 in U.S. District Court in Washington, D.C., after the agency blocked it from conducting a human study of tradipitant lasting more than 12 weeks without first doing additional animal studies on long-term safety.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below